Last reviewed · How we verify

Reproductive Health Training Center of the Republic of Moldova — Portfolio Competitive Intelligence Brief

Reproductive Health Training Center of the Republic of Moldova pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Medical abortion Medical abortion marketed Progesterone receptor antagonist + prostaglandin analog combination Progesterone receptor (PR); prostaglandin receptors (EP1, EP2, EP3, FP) Reproductive Health / Obstetrics

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Gynuity Health Projects · 1 shared drug class
  2. Hadassah Medical Organization · 1 shared drug class
  3. Planned Parenthood League of Massachusetts · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Reproductive Health Training Center of the Republic of Moldova:

Cite this brief

Drug Landscape (2026). Reproductive Health Training Center of the Republic of Moldova — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/reproductive-health-training-center-of-the-republic-of-moldova. Accessed 2026-05-17.

Related